Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Harvard Business School
Johnson and Johnson
Dow
Merck

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

EXTAVIA Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: EXTAVIA
Patents:36
Applicants:1
BLAs:1
Suppliers: see list1

US Patents for EXTAVIA

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Novartis Pharms EXTAVIA interferon beta-1b INJECTABLE; SUBCUTANEOUS 125290 001 2009-08-14   See Pricing Schutzer; Steven E. (New York, NY) 2033-08-15 RX search
Novartis Pharms EXTAVIA interferon beta-1b INJECTABLE; SUBCUTANEOUS 125290 001 2009-08-14   See Pricing MERCK SERONO SA (Coinsins, Vaud, CH) 2026-05-24 RX search
Novartis Pharms EXTAVIA interferon beta-1b INJECTABLE; SUBCUTANEOUS 125290 001 2009-08-14   See Pricing Rani Therapeutics, LLC (San Jose, CA) 2030-12-23 RX search
Novartis Pharms EXTAVIA interferon beta-1b INJECTABLE; SUBCUTANEOUS 125290 001 2009-08-14   See Pricing The Scripps Research Institute (La Jolla, CA) IRM LLC (Hamilton, BM) 2031-02-18 RX search
Novartis Pharms EXTAVIA interferon beta-1b INJECTABLE; SUBCUTANEOUS 125290 001 2009-08-14   See Pricing Tarix Pharmaceuticals Ltd. (Cambridge, MA) 2032-10-02 RX search
Novartis Pharms EXTAVIA interferon beta-1b INJECTABLE; SUBCUTANEOUS 125290 001 2009-08-14   See Pricing The Regents of the University of California (Oakland, CA) 2027-06-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for EXTAVIA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C01539200/01 Switzerland   See Pricing PRODUCT NAME: DACLIZUMAB BETA; REGISTRATION NO/DATE: AUTORISATION SWISSMEDIC 66069 26.01.2017
122016000098 Germany   See Pricing PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160701
300845 Netherlands   See Pricing PRODUCT NAME: DADIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160705
CR 2016 00058 Denmark   See Pricing PRODUCT NAME: DACLIZUMAB; REG. NO/DATE: EU/1/16/1107 20160705
16C1017 France   See Pricing PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160705
2016/052 Ireland   See Pricing PRODUCT NAME: DACLIZUMAB; REGISTRATION NO/DATE: EU/1/16/1107 20160701
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Mallinckrodt
Moodys
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.